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A B S T R A C T
The purpose of the research was to determine the influence of the hepatitis B virus on
the progression of the chronic liver disease. In the present paper, 127 patients who were
followed up for five years and who had histologically verified chronic liver disease, are
described. Fifty two of them were carriers of HBsAg, 75 patients were HBsAg negative,
but had other markers typical for a previous infection of HBV in the sera. All the pa-
tients were nonalcoholics and no drug addicts. In the sera of these 127 patients markers
of HBV were prospectively followed up: HBsAg, HBeAg, anti-HBs, anti-HBc, anti-HBe,
HBVDNA, antiHCV for C virus and anti-D for D virus. It was proved by these investiga-
tions that HBV provokes very severe chronic hepatitis: CAH (chronic active hepatitis)
and CH (cirrhosis hepatis). It was also proved that HBV replicated in 44.20 % patients,
namely, HBVDNA was positive in the sera of those patients. In 26.08 % of such patients
the mutant form of HBV was present. In spite of progressive liver disease and without
any antiviral therapy all the patients with chronic HBV cirrhosis hepatis were, after
five year-follow-up, in Child-Pugh A grade. It was found that the patients who were
HBsAg negative, but had one or more markers of HBV positive in the sera, had also a se-
vere chronic hepatitis. That group of patients remains our object of further research.
The five-years follow-up of all these patients demonstrates that it is necessary to find out
an efficient medicament against HBV chronic hepatitis. Obligatory vaccination of the
risk population against virus B remains the only prevention against this severe disease.
Introduction
According to epidemiological data
there are 350.000.000 carriers of hepati-
tis B virus in different parts of the world
and 3.000.000 people die yearly from dif-
ferent forms of chronic hepatitis caused
by this virus. Distribution of HBV is vari-
ous on different continents, respectively
in different countries1,2. About 5% of the
world population is infected with HBV.
HBV belongs to the group of hepadna vi-
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ruses with the well known structure and
genome organization3. It is transmitted
by parenteral, sexual and perinatal way.
It causes acute hepatitis, but through the
effect of HBV, chronic hepatitis forms of
various intensity develop: cirrhosis he-
patis and hepatocellular carcinoma4,5.
The investigation in Croatia demonstra-
tes that there are 2–7% of the infected
population and that HBV is a significant
cause of liver disease in our country6.
Through this investigation we wanted to
examine natural history of chronic HBV
hepatitis in our patients.
Patients and Methods
We investigated and followed up for 4
years 127 patients who had histologically
proven chronic liver disease. Within this
group there were 52 positive HBsAg pa-
tients and 75 patients who were HBsAg
negative, but who had one or more other
serum markers of HBV. After 4 years of
the follow-up we re-evaluated the sero-
logical status of these patients for HBV
and in a portion of the investigated pa-
tients we performed a control liver biopsy.
After that, we followed up the whole
group during 12 months, and every 4
months, during clinical control, we deter-
mined the HBV markers in their sera. At
the end of the investigation we again per-
formed a control liver biopsy in a portion
of the same patients. Alcohol abuse was
excluded for all patients as well as intra-
venous drugs. The history of previous
acute hepatitis, blood transfusion or
other sources of HBV infection were ta-
ken. Histological diagnosis was made ac-
cording to the accepted classification of:
chronic persistent hepatitis (CPH), chro-
nic active hepatitis (CAH), cirrhosis he-
patis (CH), hepatocellular carcinoma
(HCC) or normal findings (N)7–9. The sera
markers HBsAg, anti-HBs, anti-HBc,
HBeAg, anti HBe, were analysed by com-
mercial methods RIA and EIA (BEAD
test) Abbot Laboratories, North Chicago,
Illinois, USA. HBV-DNA-PCR was per-
formed by the Roche-Amplicor test. Anti
HCV-Elisa test by the Ortho Clinical Di-
agnostic, Rharitan, USA. Anti HD-by RIA
Abbot commercial test. The test of signifi-
cance,  2 with Yates correction for small
numbers was used.  2 was significant if
higher than 3.841, p = 0.05. The 95% in-
terval of confidence was used for results
expressed in percentage. The numbers in
brackets mean upper and lower limits of
95% interval of confidence10.
Results
Out of 127 patients with HBV mark-
ers in the sera, 47.24% (33–61%) had cir-
rhosis, 24.41% (10–43%) had chronic ac-
tive hepatitis and 23.61% (10–44%) had
chronic persistent hepatitis.
Out of 127 patients, 62.20% (48–73%)
were men. In the group of 52 HBsAg posi-
tive patients, at the first medical check-
up, 34.61% (15–60%) had cirrhosis and
30.76% (11–58%) had chronic active hep-
atitis. After 48 months we performed a
control biopsy on 9 of those patients: two
of them with previous normal findings
developed CPH and CAH, 4 patients with
previous CAH developed cirrhosis and
from 3 patients with previous CPH one
remained CPH and two developed the
CAH. It means that after 48 months of
the follow-up in this HBsAg positive
group 46.15% (25–67%) had cirrhosis he-
patis and 63.46% (4–79%) of them were
men. Women had cirrhosis in 36.54%
(69–88%) cases. The replication tests
were positive in 44.23% (24–68%) among
all 52 patients. In these patients where
HBV replicated most of them had cirrho-
sis hepatis and were male in 69.56% (60–
88%) cases. Most of our patients had ani-
cteric acute phase of HBV hepatitis be-
cause 11.53% (5–23%) of patients had a
history of previous acute hepatitis.
15.38% (2–60%) patients received blood
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transfusion and 40.38% (20–63%) proba-
bly had other unknown source of infec-
tion. In 52 patients, followed up by us for
5 years, we performed control liver biopsy
in 16 patients at the and of the investiga-
tion. Three patients with CPH developed
CH, four with CAH also developed CH
and one patient with previous CH devel-
oped HCC. Three patients in this HBsAg
positive group died after a 5-year fol-
low-up, one with HCC and two with CH
(Table 1). In 75 patients who were ABsAg
negative but were positive for other
markers of HBV, 48% (30–66%) had cir-
rhosis hepatis and 22.67% had CAH
(6–48%). Average age of these patients
was 55.4 for male and 53.4 for female.
45.3% (26–63%) of these patients were
younger than 50. Most of these patients
had only anti-HBC in the sera and they
had cirrhosis hepatis (Table 2). After 5
years of following up we did 13 control
liver biopsy in this group of 75 HBsAg
negative patients. Four of them with
CPH developed progressive hepatitis: one
of them developed CAH, three developed
cirrhosis. One patient with previous CPH
developed HCC, one patient with previ-
ous CPH had a normal finding at the con-
trol biopsy and one patient with the pre-
vious normal finding, after 5 years, deve-
loped HCC. All the patients who devel-
oped progressive hepatic disease had
anti-HBC positive (Table 3).
Serological markers of HBV in the
group of these 75 patients did not change
during that 5-year follow up. There was
no statistical significant difference in the
group with HBsAg positive patients with
severe hepatic disease in relation to
HBsAg negative patients ( 2 = 0.0619). In
the HBsAg positive patients who were
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TABLE 1
HISTOLOGICAL DISTRIBUTION OF SERA HBSAG POSITIVE PATIENTS
DURING 5 YEARS OF FOLLOW-UP
Histology First check % 4 years % 5 years %
CH 18 34.61 24 46.15 30 57.69
CAH 16 30.76 14 26.92 10 19.23
CPH 12 23.07 10 19.23 7 13.46
N 6 11.53 4 7.69 4 7.69
HCC 0 0.00 1 1.92
Total 52 52 52 100.00
TABLE 2










CH 7 13 12 2 2 36 48.00
CAH 2 7 5 1 2 17 22.66
CPH 4 4 10 2 0 20 26.67
N 0 1 0 1 0 2 2.67
Total 13 25 27 6 4 75 100.00
also HBVDNA positive, but were male
and younger than 50 there was no signifi-
cant difference in relation to the group of
male patients who had no markers if vi-
ral replications ( 2 = 2.6331). There was a
significant difference between the female
patients who had such characteristics ( 2
= 3.9327, p  0.05). It is interesting that
there is no significant difference in rela-
tion to the patients who were HBsAg pos-
itive and HBV DNA positive and the
group which was HBsAg positive and
HBVDNA negative ( 2 = 0.3421).
Discussion
At the Gastroentero-hepatologic divi-
sion of the University hospital »Merkur«
in Zagreb, the patients with chronic HBV
hepatitis have been investigated for 25
years. In 1974 it was determined that
15% of the patients with histologically
proven chronic liver disease was positive
for the HB antigen11. In 1981, when very
sensitive RIA method for determination
of serologic markers of HBV was used for
the first time, we were surprised by the
number of the patients who had HBV
chronic hepatitis. HBsAg was positive in
105 out of a total of 401 investigated pa-
tients (26%).
In 247 of all patients we founded one
or more markers for HBV12. We control-
led our patients in hospital and outpa-
tients introducing new methods of testing
for HBV in order to make better diagnosis
of chronic HBV hepatitis. This investiga-
tion shows that our patients with sero-
logical HBV markers have very severe
chronic hepatitis and that the virus hepa-
titis B is a very significant factor for de-
veloping chronic hepatitis. 5-years sur-
vival for cirrhosis and chronic active
hepatitis is 55% for the patients under 65
years of age. Such severe hepatic disease
has a fatal end and the question of ther-
apy for the patients with chronic HBV
hepatitis is a challenge13.
Antiviral therapy with interferon has
been applied for a few decades and hun-
dreds of patients were cured with various
doses of interferon at different degrees of
chronic hepatic disease with various suc-
cess14. During our investigations we did
not cure our HBV-patients with antiviral
therapy, although our patients had all
predictors for introducing such kind of
therapy: active hepatic disease, no cirrho-
sis, female gender, infection with B-virus
at adult age, low-grade of HBVDNA in
sera, and anicteric acute hepatitis. Most
of our patients, nevertheless, have cirrho-
sis hepatis and it is very risky to apply
antiviral therapy at such patients. But,
for example, Hoofnagle et al.15 gave inter-
feron to the patients with Child Pugh B
and C-grade. In 35% of the patients
HBVDNA converted and biochemistry
parameters in the patients improved.
Better effect was achieved in the group of
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TABLE 3
HISTOLOGICAL DISTRIBUTION OF HBSAG SERA NEGATIVE PATIENTS BUT POSITIVE FOR
ANTI-HBV ANTIBODIES DURING 5 YEARS OF FOLLOW-UP
Histology First check % 4 years % 5 years %
CH 30 40.00 36 48.00 39 52.00
CAH 20 26.67 17 22.67 18 24.01
CPH 17 22.67 20 26.67 14 18.67
N 8 10.66 2 2.66 2 2.66
HCC 0 0 0 0 2 2.66
Total 75 75 75 100.00
patients with Child Pugh A-degree. The
results of Perillo et al. with interferon at
the patients who had decompensated cir-
rhosis hepatis were similar, but a number
of the patients died because of complica-
tions of liver disease during the ther-
apy16. All our patients with cirrhosis
hepatis were at the beginning of investi-
gation in Child Pugh A-degree. Although
antiviral therapy was not applied with
these patients, they were in the same de-
gree of disease after 5-years follow-up.
It is interesting that in our patients
who were HBsAg positive at the begin-
ning of investigation there was no spon-
taneous sero-conversion of HBsAg, nei-
ther HBeAg. That had no effect on di-
sease development. In our investigation
we also defined a group of patients with
mutant B-virus which is characteristic
for the Mediterranean area. Such pa-
tients have very progressive liver disea-
ses but are also very resistant to antiviral
therapy17,18.
Our group of patients who are HBsAg
negative, but positive for other serolo-
gical markers, is especially interesting.
They have severe chronic hepatitis dis-
ease and our opinion is that B virus is
ethiologically a cause of liver disease be-
cause alcohol and C virus are excluded.
Among them, there is a high percentage
of patients (33%) who have only anti-HBc
positive and 44% of them have cirrhosis
hepatis. With this research we have con-
tributed to recent investigations which
points to a conclusion that it is necessary
for such patients to look for B virus with
the help of new high sensitive meth-
ods19–21.
Conclusions
We did not apply antiviral therapy in
our patients, but the investigation and
the results point to the necessity of dis-
covering of a new and more efficient ther-
apy for the HBV chronic hepatitis. Until
that time, a recommendation of WHO for
obligatory vaccination against B virus
among risky population as well as in ar-
eas with 7% infection is the only protec-
tion measure against this virus22,23.
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PROGNOZA KOD OBOLJELIH OD KRONI^NOG B HEPATITISA
S A @ E T A K
Svrha rada bila je utvrditi utjecaj hepatitis B virusa na razvoj kroni~ne bolesti jetre.
U navedenom radu pra}eno je tijekom 5 godina 127 bolesnika s histolo{ki verificira-
nom kroni~nom bole{}u jetre. 52 su bili nosioci HBsAg, a 75 su bili HBsAg negativni,
ali su imali druge biljege u serumu za preboljelu infekciju hepatitis B virusa. Svi bo-
lesnici bili su nealkoholi~ari i neovisnici o uzimanju intravenoznih droga. U svih 127
bolesnika prospektivno su pra}eni biljezi hepatitis B virusa: HBsAg, anti HBs, anti
HBc, HBeAg, HBVDNK, kao i anti HCV za C hepatitis virus i anti D za D virus. Istra-
`ivanjem je dokazano da B virus izaziva izuzetno te{ke bolesti jetre: kroni~ni aktivni
hepatitis i cirozu. Ustanovljeno je tako|er da se hepatitis B virus i dalje replicira u
44.20% bolesnika. U 26.08% takovih bolesnika dokazana je prisutnost mutantne forme
hepatitis B virusa. Unato~ progresivnoj bolesti jetre i bez antiviralne terapije s kroni-
~nom HBV cirozom jetre bili su nakon 5 godina u klini~kom Child Pugh A stadiju obo-
ljenja. Ustanovljeno je da HBsAg negativni, ali s jednim ili vi{e biljega B hepatitisa u
serumu tako|er imaju te{ka oboljenja jetre te ostaju predmetom daljnjeg istra`ivanja.
Petogodi{nje pra}enje ovih bolesnika pokazuje da je neophodno iznala`enje efikasnog
lijeka protiv hepatitis B virusne bolesti jetre, a da je obavezno cijepljenje ugro`enih
skupina za sada jedina prevencija od ovog te{kog oboljenja.
216
V. ^oli}-Cvrlje et al.: Chronic Hepatitis B, Coll. Antropol. 24 (2000) 1: 211–216
